Silence Therapeutics CEO Craig Tooman discusses navigating the rough waters of post-pandemic biotech fundraising and investment, and how a restructured organizational approach has put the company in a stronger position in the growing field of gene silencing with siRNA drugs.
Craig Tuman: Silencing the Distractions
Leave a comment
